Month: March 2021

Information for NCC patients regarding the Astra Zeneca COVID-19 vaccine

Below is a statement from the National Coagulation Centre (NCC) regarding the Astra Zeneca COVID19 vaccine: On 18/03/2021, the safety committee of the EMA released a statement which confirmed that the benefits of the Astra Zeneca COVID19 vaccine continue to outweigh the risk of side effects. In particular, there is no evidence that the vaccine …

Information for NCC patients regarding the Astra Zeneca COVID-19 vaccine Read More »

EHC Position Statement on COVID-19 AstraZeneca vaccine

The following is a statement from the European Haemophilia Consortium (EHC) commenting on the European Medicines Agency (EMA) statement regards Covid-19 AstraZeneca vaccine: 19 March 2021 The European Haemophilia Consortium (EHC) has been closely monitoring the recent safety signal of blood clots in some recipients of the COVID-19 Vaccine AstraZeneca and wishes to inform its …

EHC Position Statement on COVID-19 AstraZeneca vaccine Read More »

EMA statement regards the Covid-19 Vaccine AstraZeneca

Below is the European Medicines Agency (EMA) statement regards the Covid-19 Vaccine AstraZeneca: COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary …

EMA statement regards the Covid-19 Vaccine AstraZeneca Read More »